Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Apr 27  •  04:00PM ET
3.76
Dollar change
-0.18
Percentage change
-4.57
%
Index
RUT
P/E
-
EPS (ttm)
-1.20
Insider Own
26.35%
Shs Outstand
125.75M
Perf Week
-11.53%
Market Cap
478.24M
Forward P/E
-
EPS next Y
-0.64
Insider Trans
-14.93%
Shs Float
93.68M
Perf Month
-5.05%
Enterprise Value
656.45M
PEG
-
EPS next Q
-0.20
Inst Own
52.93%
Perf Quarter
3.87%
Income
-142.62M
P/S
5.88
EPS this Y
28.57%
Inst Trans
3.60%
Perf Half Y
-7.62%
Sales
81.36M
P/B
-
EPS next Y
20.25%
ROA
-44.16%
Perf YTD
6.52%
Book/sh
-1.48
P/C
1.83
EPS next 5Y
-
ROE
-
52W High
4.98 -24.50%
Perf Year
182.71%
Cash/sh
2.05
P/FCF
-
EPS past 3/5Y
17.66% 21.50%
ROIC
-57.01%
52W Low
1.23 206.94%
Perf 3Y
93.81%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-27.09% -
Gross Margin
90.57%
Volatility
5.19% 6.44%
Perf 5Y
-85.92%
Dividend TTM
-
EV/Sales
8.07
EPS Y/Y TTM
27.54%
Oper. Margin
-133.39%
ATR (14)
0.25
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
4.31
Sales Y/Y TTM
14.85%
Profit Margin
-175.31%
RSI (14)
41.46
Dividend Gr. 3/5Y
- -
Current Ratio
4.37
EPS Q/Q
85.39%
SMA20
-4.08%
Beta
1.89
Payout
-
Debt/Eq
-
Sales Q/Q
36.36%
SMA50
-7.54%
Rel Volume
0.87
Prev Close
3.94
Employees
193
LT Debt/Eq
-
SMA200
-0.08%
Avg Volume
881.07K
Price
3.76
IPO
May 15, 2020
Option/Short
Yes / Yes
Trades
Volume
762,252
Change
-4.57%
Date Action Analyst Rating Change Price Target Change
Nov-08-24Initiated Stephens Overweight $6
May-30-24Initiated Cantor Fitzgerald Overweight
Mar-28-24Initiated Guggenheim Buy $11
Aug-10-23Upgrade JP Morgan Underweight → Neutral
Apr-24-23Downgrade BofA Securities Neutral → Underperform $7 → $2
Dec-06-22Initiated CapitalOne Overweight $12
Nov-09-22Downgrade BofA Securities Buy → Neutral $14 → $7
Sep-21-22Initiated JP Morgan Overweight $5
Sep-09-22Downgrade Morgan Stanley Overweight → Equal-Weight $17 → $11
Nov-09-21Initiated Wolfe Research Outperform $44
Today 07:30AM
Apr-01-26 04:05PM
Mar-10-26 05:01PM
08:35AM
07:30AM
09:17AM Loading…
Mar-09-26 09:17AM
Mar-03-26 07:15AM
Mar-02-26 04:05PM
Feb-24-26 07:15AM
Feb-23-26 07:15AM
Feb-02-26 04:05PM
Jan-30-26 10:36AM
09:40AM
Jan-13-26 09:40AM
Jan-08-26 04:05PM
07:15AM Loading…
07:15AM
Jan-02-26 04:05PM
Dec-29-25 12:00PM
Dec-19-25 07:55AM
Dec-18-25 01:14AM
Dec-17-25 09:40AM
Dec-15-25 12:00PM
Dec-04-25 07:40AM
Dec-03-25 07:30AM
Dec-02-25 04:05PM
Dec-01-25 04:05PM
09:40AM
Nov-18-25 12:00PM
Nov-10-25 04:01PM
08:40AM
07:30AM Loading…
07:30AM
Nov-07-25 12:51PM
07:20AM
Nov-06-25 05:45PM
Nov-03-25 06:05PM
07:15AM
Oct-27-25 07:15AM
Oct-26-25 06:16AM
Oct-24-25 08:07AM
Oct-13-25 01:06PM
07:30AM
Oct-01-25 04:05PM
Sep-29-25 12:56AM
Sep-18-25 10:34AM
Sep-02-25 04:05PM
Aug-27-25 07:15AM
Aug-13-25 03:07AM
Aug-12-25 03:00PM
07:30AM
Aug-11-25 07:00PM
09:34AM
Aug-07-25 06:10PM
Aug-05-25 04:05PM
Aug-04-25 09:40AM
Aug-01-25 04:05PM
Jul-01-25 04:05PM
Jun-26-25 11:44AM
Jun-16-25 07:15AM
Jun-12-25 06:45AM
06:30AM
Jun-02-25 04:05PM
May-30-25 05:44AM
May-15-25 07:49AM
07:15AM
May-14-25 09:10AM
08:00AM
07:45AM
May-13-25 09:42AM
May-08-25 05:50PM
07:15AM
May-01-25 05:25PM
Apr-30-25 08:15AM
Apr-29-25 10:01AM
Apr-28-25 10:00AM
07:00AM
Apr-01-25 04:05PM
07:15AM
Mar-31-25 09:00PM
Mar-27-25 11:17AM
08:35AM
07:30AM
Mar-25-25 05:30PM
Mar-24-25 11:08PM
Mar-20-25 07:15AM
Feb-03-25 04:05PM
Jan-30-25 07:15AM
Jan-02-25 04:05PM
Dec-30-24 04:30PM
Dec-11-24 07:30AM
Dec-09-24 07:30AM
Dec-06-24 07:30AM
Dec-02-24 04:30PM
Nov-14-24 02:02AM
Nov-08-24 01:14PM
Nov-07-24 08:50AM
07:30AM
Nov-06-24 07:41AM
Nov-05-24 09:47AM
Nov-04-24 07:15AM
Nov-01-24 04:05PM
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Redmile Group, LLC10% OwnerApr 02 '26Sale3.282,634,5068,638,54512,666,731Apr 02 09:00 PM
Redmile Group, LLC10% OwnerApr 02 '26Sale3.282,529,4918,294,20110,265,297Apr 02 09:00 PM
Redmile Group, LLC10% OwnerMar 31 '26Sale3.75196,229736,25115,470,502Apr 02 09:00 PM
Redmile Group, LLC10% OwnerMar 31 '26Sale3.75188,407706,90312,957,305Apr 02 09:00 PM
Redmile Group, LLC10% OwnerApr 01 '26Sale3.80169,265643,03815,301,237Apr 02 09:00 PM
Redmile Group, LLC10% OwnerApr 01 '26Sale3.80162,517617,40212,794,788Apr 02 09:00 PM